CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体对比 CAR-T 细胞治疗复发/难治性弥漫大 B 细胞淋巴瘤：疗效、安全性与可及性的比较性叙述综述
英文原题：Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility.
查看英文原题
Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本综述为临床医生提供了全面的比较，以支持复发/难治性 DLBCL 的循证治疗选择。
中文摘要
方法
本叙述性综述从作用机制、临床疗效、安全性、物流、成本及可及性等多个方面比较这些疗法。
结果
CAR-T 疗法显示持久完全缓解率为40%–60%，无进展生存期延长（中位11–12.5个月），但受制于制备复杂、成本高和可能出现的严重毒性。相比之下，BsAb可即刻提供现货型治疗，具有良好疗效和更优安全性，适合门诊给药，但其长期持久性仍在研究中。
结论
本综述为临床医生提供全面比较，以支持rel/ref DLBCL的循证治疗选择。
展开英文摘要原文
METHODS
This narrative review compares these therapies across multiple domains, including mechanisms of action, clinical efficacy, safety profiles, logistics, cost, and accessibility.
RESULTS
CAR T therapies have demonstrated durable complete response rates (40%-60%) and extended progression-free survival (median 11-12.5 months), but they are limited by complex manufacturing, high cost, and potentially severe toxicities. In contrast, BsAbs offer immediate, off-the-shelf availability, with promising efficacy and a more favorable safety profile that enables outpatient administration, although long-term durability remains under investigation.
CONCLUSION
This review provides clinicians with a comprehensive comparison to support evidence-based treatment selection in rel/ref DLBCL.
论文信息
- 作者
- Abou DS、Thalib HI、Akil F、Sabbagh SZ、Abou HS、Pereira M、Hassan FE
- 第一作者单位
- Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.Saudi Arabia
- 通讯作者单位
- General Medicine Practice Program, Department of Physiology, Batterjee Medical College, Jeddah, Saudi Arabia.Saudi Arabia
- 文献类型
- 综述 · 对照研究
- 期刊
- Cancer medicine2026 Feb
- 原文标识
- PubMed 41608764 · DOI 10.1002/cam4.71562
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →